Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma

This retrospective study investigated the clinical efficacy and safety of bortezomib retreatment in patients with relapsed or refractory multiple myeloma (MM). A total of 30 patients who relapsed or progressed after ≥6 months since the last dose of their previous bortezomib therapy were included in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biomed Res Int
Asıl Yazarlar: Ahn, Jae-Sook, Jung, Sung-Hoon, Lee, Seung-Shin, Ahn, Seo-Yeon, Yang, Deok-Hwan, Kim, Yeo-Kyeoung, Kim, Hyeoung-Joon, Lee, Je-Jung
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Hindawi Publishing Corporation 2014
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4233662/
https://ncbi.nlm.nih.gov/pubmed/25530955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/145843
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller